Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: The efficacy and safety of tislelizumab combined with gemcitabine plus cisplatin in the treatment of postoperative patients with muscle-invasive upper tract urothelial carcinoma

Fig. 2

Comparison of disease-free survival between patients in the tislelizumab combined with gemcitabine plus cisplatin chemotherapy (TGC) group and the Surveillance group. The median DFS of the surveillance group was 16.5 [95% confidence interval (CI), 14.7–18.3] months, while the median DFS of the TGC group has not yet been reached [hazard ratio (HR) 0.367 (95% CI, 0.169–0.796); p = 0.008]. Compared with the surveillance group, the combination therapy group had dramatically improved DFS after RNU and reduced risk by 63.3%

TGC: tislelizumab combined with gemcitabine plus cisplatin

HR: hazard ratio

CI: confidence interval

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us